The Legal 500 view: Healthy competition
The Legal 500’s life science and healthcare industry focus ranking was introduced three years ago to recognise firms with dedicated…
Life Sciences Yearbook 2024
Life Sciences Yearbook 2024 – Editor’s letter
Welcome to the 2024 Life Sciences Yearbook from the Legal 500 and Legal Business, sponsored by Herbert Smith Freehills. This…
Sponsored thought leadership: China life sciences – Transaction insights and notable industry trends
China’s life sciences and healthcare (LS&H) industry underwent an unprecedented transformation in 2023 consisting of numerous challenges and opportunities. Within…
Sponsored Q&A: Fangda Partners
1. What are the current regulatory frameworks governing the life sciences industry in China, and how have they evolved in…
‘You’d be a brave innovator to ignore the UK’ – why patent work is booming in the post-Brexit UK life sciences market
Buzz about blockbuster drug developments, expiring patents and the launch of the European Union’s Unified Patent Court – 2023 certainly…
Taking back control – the post-pandemic landscape for life sciences regulation
After years of delays caused by geopolitical instability and the Covid-19 pandemic, the new regulatory landscape for the life sciences…
Life Sciences perspectives: Grant Castle
Why did you decide to specialise in life sciences? I have a science background – a PhD in organic chemistry…
Rising stars: Zina Chatzidimitriadou – ‘It is the one legal area that affects every single one of us and is, above all, human-centred’
Zina Chatzidimitriadou, senior managing associate at Sidley, on why she picked a career in life sciences law Why did you…
Rising stars: Jaspreet Takhar – ‘EU regulators are preparing an avalanche of new laws that are going to have a monumental impact on pharma and medtech’
Baker McKenzie’s Jaspreet Takhar on the future of digital health solutions What made you decide to specialise in life sciences…
Rising stars: Dr Chris Boyle – ‘AI is going to have a transformative impact on the life sciences industry’
Dr Chris Boyle, counsel at Sidley, on the risks and opportunities facing the industry What do you most enjoy about…
Rising stars: David Gibson – ‘There are so many great new technologies and medicines with potential to make a difference to populations and treatment pathways but key challenges remain in regulating them’
David Gibson, senior associate at McDermott Will & Emery Why did you decide to specialise in life sciences law, and…